title: Feeding and drinking behaviour following angiotensin converting enzyme blockade: role of injectant pH.
abstract: Angiotensin converting enzyme (ACE) is a circulating dipeptidase which has a broad specificity and is known to metabolise a range of circulating peptides. While a number of circulating peptides are believed to modulate food intake, it is not known if ACE plays a role in the control of feeding behaviour and therefore in this study we have examined the effect of the potent, specific ACE antagonists captopril (SQ 14225) and enalapril (MK421) on food and water intake following food deprivation and 2-deoxyglucose treatment in the rat. One hour captopril (50 mg/kg, IP) pretreatment significantly reduced the food intake of 24 hr food deprived rats. Because captopril solutions have a low pH (2.0), the effect of buffered captopril on food intake following 24 hr food deprivation was also examined. Buffered captopril also significantly reduced the food intake of 24 hr food deprived rats, but not to the same extent as unbuffered captopril. Naloxone pretreatment (1 mg/kg, IP) did not antagonize the effect of captopril on food intake indicating that the anorexic action of captopril was not due to alterations in opiate peptide levels. Buffered captopril did not reduce the food intake of food-replete rats receiving 2-deoxyglucose (300 mg/kg, IP) or alter blood gases or pH. However, an equimolar buffered dose of the structurally different ACE inhibitor enalapril failed to significantly alter food deprivation-induced food intake, suggesting that this action of captopril in reducing food intake was unrelated to ACE blockade.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Physiology, University of Melbourne, Parkville, Victoria, Australia.
authors.forename: R
authors.initials: R
authors.lastname: Di Nicolantonio
authors.forename: R S
authors.initials: RS
authors.lastname: Weisinger
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D002216:Captopril / Q000494:pharmacology; D003847:Deoxyglucose / Q000494:pharmacology; D004327:Drinking Behavior / Q000187:drug effects* / Q000502:physiology; D005247:Feeding Behavior / Q000187:drug effects* / Q000502:physiology; D006863:Hydrogen-Ion Concentration; D007274:Injections, Intraperitoneal; D008297:Male; D009270:Naloxone / Q000494:pharmacology; D007703:Peptidyl-Dipeptidase A / Q000502:physiology; D051381:Rats
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D009270:Naloxone; D003847:Deoxyglucose; D002216:Captopril; D007703:Peptidyl-Dipeptidase A